No overdiagnosis of ADHD, say experts
Experts are warning that far from being over diagnosed, people with ADHD are waiting too long for assessment, support and treatment. In a paper, published today in the British… read more.
Experts are warning that far from being over diagnosed, people with ADHD are waiting too long for assessment, support and treatment. In a paper, published today in the British… read more.
Youth football accounts for the largest share of sports‑related traumatic brain injuries (TBIs) in children and young adults, nearly one in every five TBIs, according to a preliminary… read more.
Canadian researchers report that new stimulant prescriptions to treat ADHD among adults have more than doubled since the start of the COVID-19 pandemic. And this finding was especially… read more.
The EMA has recommended the refusal of the marketing authorisation for Daybue, intended for the treatment of Rett syndrome, a rare inherited condition that affects the brain and… read more.
Glucagon-like peptide-1 (GLP-1) receptor agonists used to treat type 2 diabetes and obesity may also help to lower the risk of addiction to a range of substances including… read more.
The EMA has recommended the refusal of the marketing authorisation for Iloperidone Vanda Pharmaceuticals, a medicine intended for the treatment of schizophrenia and manic or mixed episodes associated… read more.
For the many patients with depression who haven’t found relief through medication, transcranial magnetic stimulation (TMS) — a noninvasive therapy that uses magnetic pulses to stimulate specific areas… read more.
NICE(UK): Cerliponase alfa is not recommended, within its marketing authorisation, for treating neuronal ceroid lipofuscinosis type 2 (CLN2; also known as tripeptidyl peptidase 1 deficiency). This recommendation is not intended… read more.
A large registry study in Finland by the University of Oulu and the University of Eastern Finland shows that many older adults receive antipsychotic medications for purposes other… read more.
AbbVie announced that it has received marketing approval in Japan for Aquipta tablets (atogepant), a calcitonin gene-related peptide (CGRP) receptor antagonist, for the prevention of migraine attacks in… read more.
BioXcel Therapeutics Inc. announced the completion of an updated market opportunity assessment for Igalmi (dexmedetomidine) for acute agitation associated with bipolar disorders or schizophrenia in the at-home (outpatient)… read more.
Researchers report that patients diagnosed with cancer who subsequently develop a mental disorder are at an increased risk of all-cause death. The findings were published on Feb. 23,… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.